Results 141 to 150 of about 40,708 (270)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 30-32, January 2026.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

Patient Preference and Adherence, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
doaj  

Vareniclina. Un paso más en la lucha contra el tabaquismo [PDF]

, 2007
Recientemente la Food and Drugs Administration ha aprobado Vareniclina, fármaco para la deshabituación tabáquica que presenta un novedoso mecanismo de acción, agonismo parcial de receptores nicotínicos de acetilcolina a4ß2.Hemos revisado la farmacología,
Donat, Lucas, Ferrando Piqueres, Raúl, Martínez, Beatriz, Milara Payá, Javier, Pérez Prior, Noemí, Soler Company, Enrique   +5 more
core  

Validation of a liquid chromatography–mass spectrometry method to assess the metabolism of bupropion in rat everted gut sacs

, 2005
Cécile Arellano, Claude Philibert, Christelle Vachoux, John M. Woodley, Georges Houin   +4 more
openalex   +2 more sources

Bupropion, Bayesian Logic and Serotonin Toxicity [PDF]

, 2010
Peter Kenneth Gillman
openalex   +1 more source

Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 1, January 2026.
ABSTRACT Objectives Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing public health concern that contributes to liver and cardiovascular complications. The prevalence of MASLD in women increases sharply around age 50 years, but the relationship between an earlier age at natural menopause and MASLD is unknown.
Joshua Stokar, Rivka Dresner‐Pollak
wiley   +1 more source

Inhibition of Under-Deposit Corrosion of Carbon Steel by Bupropion Drug in CO2 Saturated Brine Solutions

, 2020
Ali Sorkh Kaman Zadeh, M. Shahidi, Maryam Kazemipour   +2 more
openalex   +1 more source

Restoration of Serotonin Neuronal Firing Following Long-Term Administration of Bupropion but Not Paroxetine in Olfactory Bulbectomized Rats [PDF]

, 2014
Mostafa El Mansari, Stella Manta, Chris A. Oosterhof, Kareem S El Iskandrani, Franck Chenu, Stacey Shim, Pierre Blier   +6 more
openalex   +1 more source

The Efficacy of Pharmacological Treatment of Depression in Anorexia Nervosa and Underweight Patients: A Systematic Review

European Eating Disorders Review, Volume 34, Issue 1, Page 55-70, January 2026.
ABSTRACT Objective Major depressive disorder (MDD) is a frequent comorbidity in anorexia nervosa (AN). This review aimed to evaluate evidence on the effectiveness of pharmacological treatments for MDD in underweight individuals. Method A systematic review was conducted using PubMed, Medline, PsycINFO, and Web of Science through March 2025.
M. J. Besjes, S. H. W. Mares, A. A. van Elburg, J. Spijker   +3 more
wiley   +1 more source

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

, 2022
Carlos M. Grilo, Janet A. Lydecker, Sarah K. Fineberg, Jorge O. Moreno, Valentina Ivezaj, Ralitza Gueorguieva   +5 more
openalex   +2 more sources